MedTrace Logo

Evaluation of Add on Enstilar in Patients Using Otezla for Psoriasis

NCT03587194 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-04-16

Study results available
· View outcomes & findings →

Summary

Add-on Enstilar to Otezla therapy.

Conditions

Interventions

DRUG

Otezla

Otezla 30mg BID

Sponsors & Collaborators

  • Celgene Corporation

    collaborator INDUSTRY

  • Psoriasis Treatment Center of Central New Jersey

    lead OTHER

Principal Investigators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-23
Primary Completion
2019-07-01
Completion
2019-07-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03587194 on ClinicalTrials.gov